## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

Art Unit: 1621

CHAN ET AL.

Examiner: Samule A. Barts

INTERNATIONAL APPLICATION NO: PCT/CN2005/000291

**FILED: 10 MARCH 2005** 

U.S. APPLICATION NO: 10/590,544

35 USC §371 DATE:

FOR: CHIRAL TERTIARY AMINOALKYLNAPHTHOLS

**MS: Amendment** 

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is supplemental to the Information Disclosure Statement filed August 25, 2006. Since it is being filed in accordance with 37 C.F.R. §1.97(c), a letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

These references were cited in a search report in a corresponding European application. Copies of these references and the search report are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

hn W. Kung

Attorney for Applicants Reg. No. 44,199

Novartis Pharmaceuticals Corp. Patents Pharma One Health Plaza, Building 104 East Hanover, NJ 07936-1080 (862) 778-7877

Date:

7/22/08